Attovia Therapeutics, Inc.
ATTOHealthcare|Biotechnology|US
$15.27
+0.27 (+1.80%)
DCF Value
$0.98
Tangible Book / Share
$2.47
Cash / Share
$2.52
Clinical Trials (4)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07833306 Efficacy and Safety of ATTO-1310 in the Treatment of Participants With Chronic Pruritus of Unknown Origin | Chronic Pruritus of Unknown Origin | P2 | Not Yet Recruiting | 300 | RCT, Double-blind | ATTO-1310, Placebo |
| NCT07205081 Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis | Normal Volunteers, Atopic Dermatitis (AD) | P1 | Completed | 48 | RCT, Double-blind | ATTO-3712, Placebo |
| NCT06787586 Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus | Normal Volunteers, Atopic Dermatitis (AD) | P1 | Completed | 108 | RCT, Double-blind | ATTO-1310, ATTO-1310 Placebo |
| NCT07819799 Safety, Tolerability and PK of ATTO 1091 in Healthy Adult Volunteers and Patients With Ulcerative Colitis | Ulcerative Colitis (UC) | P1 | Not Yet Recruiting | 96 | RCT, Double-blind | ATTO-1091, Placebo |